<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>RNA</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>COVID-19 mRNA vaccine provides broad-spectrum protection</title>
      <description>
        <![CDATA[Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730096</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730096-covid-19-mrna-vaccine-provides-broad-spectrum-protection</link>
    </item>
    <item>
      <title>siRNA-mediated targeting of IRS2 in TNBC optimized with albumin-binding dendrimers</title>
      <description>
        <![CDATA[Effective targeted therapies against aggressive breast cancer subtypes, such as triple-negative breast cancer (TNBC), are still lacking. Developing therapeutics targeting nonenzymatic, intracellular proteins with causal roles in TNBC progression remains a significant challenge.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728632</guid>
      <pubDate>Thu, 05 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728632-sirna-mediated-targeting-of-irs2-in-tnbc-optimized-with-albumin-binding-dendrimers</link>
    </item>
    <item>
      <title>Vaccines: From the toast of the town to being in the crosshairs</title>
      <description>
        <![CDATA[BioWorld’s 2022 end-of-year highlights included a toast to the future – of universal vaccines. Even before SARS-CoV-2 vaccines were developed in record time and saved countless lives during the COVID-19 pandemic, vaccines were a rare bright spot in the fight against infectious diseases. Bacteria are becoming multidrug resistant far faster than new classes of antibiotics are being developed, viral spillover events and vector ranges are increasing, and climate change is helping bacteria and fungi alike breach human thermal protections against infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727420</guid>
      <pubDate>Tue, 23 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727420-vaccines-from-the-toast-of-the-town-to-being-in-the-crosshairs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/COVID-19-vaccine-domino.webp?t=1766503415" type="image/jpeg" medium="image" fileSize="195425">
        <media:title type="plain">COVID-19 vial in a line of toppled dominoes</media:title>
      </media:content>
    </item>
    <item>
      <title>Cancer vaccines face collateral damage of mRNA funding cuts</title>
      <description>
        <![CDATA[When Robert Kennedy Jr. announced the cancellation of 22 projects related to mRNA vaccines and the end of new investments in that technology, the U.S. Secretary of Health only mentioned their use against respiratory viruses, without referring to other applications. The vaccines whose safety and effectiveness Kennedy is questioning are based on the same molecular principles as cancer vaccines under development. “Continued investment in mRNA technology is essential to fully realize its potential in oncology and ensure that promising strategies like neoantigen-based vaccines reach clinical application.” Kazuhiro Kakimi, professor at the Department of Immunology at Kindai University Faculty of Medicine, told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724274</guid>
      <pubDate>Wed, 17 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724274-cancer-vaccines-face-collateral-damage-of-mrna-funding-cuts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Syringe-in-spotlight.webp?t=1750715555" type="image/jpeg" medium="image" fileSize="390397">
        <media:title type="plain">Syringe in spotlight</media:title>
      </media:content>
    </item>
    <item>
      <title>Animosity toward mRNA COVID vaccines puts basic science at risk</title>
      <description>
        <![CDATA[An ongoing concern for scientists is that there will be across-the-board funding cuts. This is already happening in mRNA research, where reductions affected coronavirus-related projects. During the pandemic, efforts focused on this pathogen, and once the health emergency was over, grants for antivirals were eliminated. However, these drugs could stem future outbreaks. Despite the cuts, recent research continues to demonstrate the potential of mRNA, not only for the development of antivirals, but also for obtaining more effective and longer-lasting vaccines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724254</guid>
      <pubDate>Tue, 16 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724254-animosity-toward-mrna-covid-vaccines-puts-basic-science-at-risk</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-structure/mrna-vaccine-structure-illustration.webp?t=1758032872" type="image/jpeg" medium="image" fileSize="236451">
        <media:title type="plain">mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles</media:title>
      </media:content>
    </item>
    <item>
      <title>The domino effect of cutting mRNA vaccine research</title>
      <description>
        <![CDATA[In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing therapies for viral infections, cancer, and genetic conditions. What happens to mRNA innovation when funding dries up? This series explores how reductions in funding could impact mRNA technology, affecting innovation, research and future therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724135</guid>
      <pubDate>Mon, 15 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724135-the-domino-effect-of-cutting-mrna-vaccine-research</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vial-and-syringe-in-row-of-dominoes.webp?t=1757947841" type="image/jpeg" medium="image" fileSize="621313">
        <media:title type="plain">Vial and syringe in row of dominoes</media:title>
      </media:content>
    </item>
    <item>
      <title>Rare immune disease inspires broad-spectrum antiviral mRNA</title>
      <description>
        <![CDATA[Deficiencies in interferon-stimulated gene 15 (ISG15), a protein that normally regulates the immune response, causes mild but persistent inflammation. However, its absence also provides an unexpected advantage by increasing resistance to viral infections. Inspired by this condition and using mRNA technology, scientists at Columbia University and the Icahn School of Medicine at Mount Sinai have developed a broad-spectrum antiviral platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723604</guid>
      <pubDate>Fri, 22 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723604-rare-immune-disease-inspires-broad-spectrum-antiviral-mrna</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Viruses.webp?t=1745260343" type="image/jpeg" medium="image" fileSize="359115">
        <media:title type="plain">Viruses </media:title>
      </media:content>
    </item>
    <item>
      <title>Rare immune disease inspires broad-spectrum antiviral mRNA</title>
      <description>
        <![CDATA[Deficiencies in interferon-stimulated gene 15 (ISG15), a protein that normally regulates the immune response, causes mild but persistent inflammation. However, its absence also provides an unexpected advantage by increasing resistance to viral infections. Inspired by this condition and using mRNA technology, scientists at Columbia University and the Icahn School of Medicine at Mount Sinai have developed a broad-spectrum antiviral platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723478</guid>
      <pubDate>Thu, 21 Aug 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723478-rare-immune-disease-inspires-broad-spectrum-antiviral-mrna</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Viruses.webp?t=1745260343" type="image/jpeg" medium="image" fileSize="359115">
        <media:title type="plain">Viruses </media:title>
      </media:content>
    </item>
    <item>
      <title>New preclinical data support further development of Orbital Therapeutics’ OTX-201</title>
      <description>
        <![CDATA[Orbital Therapeutics Inc. has presented preclinical results supporting the development of OTX-201, a potential best-in-class in vivo CAR T therapy that comprises an optimized circular RNA encoding a CD19-targeted CAR delivered via targeted lipid nanoparticles.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722404</guid>
      <pubDate>Wed, 23 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722404-new-preclinical-data-support-further-development-of-orbital-therapeutics-otx-201</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/B-cell-releasing-antibodies.webp?t=1720105710" type="image/jpeg" medium="image" fileSize="122329">
        <media:title type="plain">B-cell releasing antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Preclinical data for Wave’s INHIBE GalNAc-siRNA in obesity</title>
      <description>
        <![CDATA[At the recent American Society of Gene and Cell Therapy (ASGCT) meeting, Wave Life Sciences Ltd. presented siRNAs designed to suppress expression of the liver gene inhibin subunit β E (<em>INHBE</em>). Human genetic data show that heterozygous <em>INHBE</em> loss-of-function carriers exhibit a healthy metabolic profile.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720305</guid>
      <pubDate>Mon, 19 May 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720305-preclinical-data-for-waves-inhibe-galnac-sirna-in-obesity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Man-measuring-waist.webp?t=1696021724" type="image/jpeg" medium="image" fileSize="195747">
        <media:title type="plain">Man measuring waist</media:title>
      </media:content>
    </item>
    <item>
      <title>Ono and Reborna partner to discover RNA-targeting small molecules for neurological disorders</title>
      <description>
        <![CDATA[Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718817</guid>
      <pubDate>Tue, 01 Apr 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718817-ono-and-reborna-partner-to-discover-rna-targeting-small-molecules-for-neurological-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Ono and Reborna partner to discover RNA-targeting small molecules for neurological disorders</title>
      <description>
        <![CDATA[Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718744</guid>
      <pubDate>Mon, 31 Mar 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718744-ono-and-reborna-partner-to-discover-rna-targeting-small-molecules-for-neurological-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>SA-1211, a dual-target siRNA with promising antiviral activity in AAV-HBV mice</title>
      <description>
        <![CDATA[Researchers from Suzhou Siran Biotech Co. Ltd. presented the discovery and preclinical characterization of SA-1211, an <em>N</em>-acetylgalactosamine (GalNAc)-conjugated siRNA dimer targeting both hepatitis B virus (HBV) and PD-L1 gene expression, being developed as a potential new therapeutic candidate for the treatment of chronic hepatitis B (CHB).]]>
      </description>
      <guid>http://www.bioworld.com/articles/715090</guid>
      <pubDate>Wed, 04 Dec 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715090-sa-1211-a-dual-target-sirna-with-promising-antiviral-activity-in-aav-hbv-mice</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Hepatitis-B-virus.webp?t=1589308217" type="image/png" medium="image" fileSize="338579">
        <media:title type="plain">Hepatitis B virus </media:title>
      </media:content>
    </item>
    <item>
      <title>Switch Therapeutics nominates liver-sparing APOE RNAi therapy as development candidate for Alzheimer’s</title>
      <description>
        <![CDATA[Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s conditionally activated siRNA (CASi)-APOE program is designed to knock down APOE in the CNS without affecting APOE in the liver, where it plays a vital role in systemic lipid homeostasis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715020</guid>
      <pubDate>Wed, 04 Dec 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715020-switch-therapeutics-nominates-liver-sparing-apoe-rnai-therapy-as-development-candidate-for-alzheimers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Alzheimers-illustration.webp?t=1604527274" type="image/png" medium="image" fileSize="407999">
        <media:title type="plain">Elderly hands holding broken brain structure</media:title>
      </media:content>
    </item>
    <item>
      <title>A novel mRNA-LNP vaccine facilitates &lt;em&gt;Clostridioides difficile&lt;/em&gt; control</title>
      <description>
        <![CDATA[<em>Clostridioides difficile</em> is traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania developed an mRNA-LNP vaccine with promising results in preventing and controlling <em>C. difficile</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713476</guid>
      <pubDate>Fri, 11 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713476-a-novel-mrna-lnp-vaccine-facilitates-emclostridioides-difficile-em-control</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Clostridium-difficile-bacteria.webp?t=1592596059" type="image/png" medium="image" fileSize="341622">
        <media:title type="plain">Clostridium difficile bacteria</media:title>
      </media:content>
    </item>
    <item>
      <title>A novel mRNA-LNP vaccine facilitates &lt;em&gt;Clostridioides difficile&lt;/em&gt; control</title>
      <description>
        <![CDATA[<em>Clostridioides difficile</em> has been traditionally isolated from health care facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania have developed an mRNA-LNP vaccine with promising results in preventing and controlling <em>C. difficile</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713451</guid>
      <pubDate>Fri, 11 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713451-a-novel-mrna-lnp-vaccine-facilitates-emclostridioides-difficile-em-control</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Clostridium-difficile-bacteria.webp?t=1592596059" type="image/png" medium="image" fileSize="341622">
        <media:title type="plain">Clostridium difficile bacteria</media:title>
      </media:content>
    </item>
    <item>
      <title>A novel mRNA-LNP vaccine facilitates &lt;em&gt;Clostridioides difficile&lt;/em&gt; control</title>
      <description>
        <![CDATA[<em>Clostridioides difficile</em> has been traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania have developed an mRNA-LNP vaccine with promising results in preventing and controlling <em>C. difficile</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713313</guid>
      <pubDate>Thu, 10 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713313-a-novel-mrna-lnp-vaccine-facilitates-emclostridioides-difficile-em-control</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Clostridium-difficile-bacteria.webp?t=1592596059" type="image/png" medium="image" fileSize="341622">
        <media:title type="plain">Clostridium difficile bacteria</media:title>
      </media:content>
    </item>
    <item>
      <title>City Therapeutics launches with focus on RNAi-based medicine</title>
      <description>
        <![CDATA[City Therapeutics Inc. has launched with a focus on RNA interference (RNAi)-based medicine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713269</guid>
      <pubDate>Wed, 09 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713269-city-therapeutics-launches-with-focus-on-rnai-based-medicine</link>
    </item>
    <item>
      <title>Two win Nobel for microRNA work</title>
      <description>
        <![CDATA[Research into the regulation of gene expression experienced a significant breakthrough with the discovery of microRNA, small RNA molecules that do not code for proteins but control their translation. This finding has earned its discoverers – Victor Ambros and Gary Ruvkun – the 2024 Nobel Prize in Physiology or Medicine “for the discovery of microRNA and its role in post-transcriptional gene regulation.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/713308</guid>
      <pubDate>Tue, 08 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713308-two-win-nobel-for-microrna-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Nobel-Hero-Victor-Ambros-Gary-Ruvkun.webp?t=1728323503" type="image/jpeg" medium="image" fileSize="455696">
        <media:title type="plain">Illustration of Victor Ambros and Gary Ruvkun</media:title>
      </media:content>
    </item>
    <item>
      <title>Nobel Prize in Physiology or Medicine for discovering microRNA</title>
      <description>
        <![CDATA[Research into the regulation of gene expression experienced a significant breakthrough with the discovery of microRNA, small RNA molecules that do not code for proteins but control their translation. This finding has earned its authors Victor Ambros and Gary Ruvkun the 2024 Nobel Prize in Physiology or Medicine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713249</guid>
      <pubDate>Mon, 07 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713249-nobel-prize-in-physiology-or-medicine-for-discovering-microrna</link>
    </item>
    <item>
      <title>Two win Nobel for microRNA work</title>
      <description>
        <![CDATA[Research into the regulation of gene expression experienced a significant breakthrough with the discovery of microRNA, small RNA molecules that do not code for proteins but control their translation. This finding has earned its discoverers – Victor Ambros and Gary Ruvkun – the 2024 Nobel Prize in Physiology or Medicine “for the discovery of microRNA and its role in post-transcriptional gene regulation.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/713182</guid>
      <pubDate>Mon, 07 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713182-two-win-nobel-for-microrna-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Nobel-Hero-Victor-Ambros-Gary-Ruvkun.webp?t=1728323503" type="image/jpeg" medium="image" fileSize="455696">
        <media:title type="plain">Illustration of Victor Ambros and Gary Ruvkun</media:title>
      </media:content>
    </item>
    <item>
      <title>Arrowhead takes aim at obesity</title>
      <description>
        <![CDATA[Arrowhead Pharmaceuticals Inc. announced its plans to advance its RNAi drug candidates ARO-INHBE and ARO-ALK7 into clinical trials for the treatment of obesity and metabolic diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711544</guid>
      <pubDate>Fri, 16 Aug 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711544-arrowhead-takes-aim-at-obesity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Male-feet-on-scale.webp?t=1699653457" type="image/jpeg" medium="image" fileSize="357330">
        <media:title type="plain">Feet on scale</media:title>
      </media:content>
    </item>
    <item>
      <title>Airna’s series A to bring lead project into clinic, develop pipeline</title>
      <description>
        <![CDATA[Airna Corp. Inc., of Cambridge, Mass., announced it has closed an oversubscribed $60 million financing round, bringing its total series A funding to $90 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711171</guid>
      <pubDate>Fri, 02 Aug 2024 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711171-airnas-series-a-to-bring-lead-project-into-clinic-develop-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RD-money.webp?t=1588877677" type="image/png" medium="image" fileSize="578436">
        <media:title type="plain">Dollar sign droplet above test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>IN-016 granted orphan status for progressive familial intrahepatic cholestasis therapy</title>
      <description>
        <![CDATA[Innorna Co. Ltd.’s IN-016 has received orphan drug status from the U.S. FDA for the treatment of progressive familial intrahepatic cholestasis (PFIC). Earlier in July, IN-016 had been granted Rare Pediatric Disease Designation. PFIC is a group of rare genetic disorders associated with defects in bile acid secretion or transport, resulting in unwanted bile accumulation within the liver.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711168</guid>
      <pubDate>Fri, 02 Aug 2024 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711168-in-016-granted-orphan-status-for-progressive-familial-intrahepatic-cholestasis-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-and-DNA.webp?t=1602177503" type="image/png" medium="image" fileSize="311397">
        <media:title type="plain">Liver and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Triastek, Biontech to collaborate on orally available RNA drugs</title>
      <description>
        <![CDATA[Triastek Inc. and Biontech SE have entered into a research collaboration and platform technology license agreement for the development of RNA therapeutics for oral delivery based on Triastek’s Melt Extrusion Deposition (MED) 3D printing technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710762</guid>
      <pubDate>Wed, 24 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710762-triastek-biontech-to-collaborate-on-orally-available-rna-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA.webp?t=1588877759" type="image/png" medium="image" fileSize="573352">
        <media:title type="plain">RNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Liver-targeted siRNA improves body composition in mouse models</title>
      <description>
        <![CDATA[Large-scale human genetic studies have revealed that loss-of-function INHBE variants are associated with a lower abdominal to gluteofemoral fat ratio, improved metabolic profile, and reduced fasting glucose levels.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710165</guid>
      <pubDate>Mon, 08 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710165-liver-targeted-sirna-improves-body-composition-in-mouse-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration-purple.webp?t=1705415419" type="image/jpeg" medium="image" fileSize="218236">
        <media:title type="plain">Liver illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>Molecure reports advances within mRNA discovery platform</title>
      <description>
        <![CDATA[Molecure SA has confirmed the in vitro activity of a molecule binding to a new mRNA target within its mRNA discovery platform. This represents the discovery of another class of molecules binding to a second mRNA biological target, which has been confirmed in in vitro assays.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709437</guid>
      <pubDate>Thu, 13 Jun 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709437-molecure-reports-advances-within-mrna-discovery-platform</link>
    </item>
    <item>
      <title>Preclinical H5 mRNA vaccine immunizes and prevents mortality</title>
      <description>
        <![CDATA[A preclinical trial in mice and ferrets of an experimental mRNA vaccine against the H5 highly pathogenic avian influenza (HPAI) virus generated neutralizing antibodies and prevented severe illness and mortality of the animals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709298</guid>
      <pubDate>Fri, 07 Jun 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709298-preclinical-h5-mrna-vaccine-immunizes-and-prevents-mortality</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/avian-influenza-bird-flu.webp?t=1717770702" type="image/jpeg" medium="image" fileSize="145397">
        <media:title type="plain">AI-generated image of person in hazmat suit in poultry farm with chickens out of focus in the background</media:title>
      </media:content>
    </item>
    <item>
      <title>Achilles and Arcturus collaborate on sa-mRNA personalized cancer vaccines</title>
      <description>
        <![CDATA[Achilles Therapeutics plc has established a research collaboration with Arcturus Therapeutics Holdings Inc. to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines targeting clonal neoantigens.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708829</guid>
      <pubDate>Thu, 23 May 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708829-achilles-and-arcturus-collaborate-on-sa-mrna-personalized-cancer-vaccines</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Vaccine-research-vial-syringe.webp?t=1670859743" type="image/png" medium="image" fileSize="1080600">
        <media:title type="plain">Vaccine vial and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>RZ-001 shows promise for treating glioblastoma multiforme</title>
      <description>
        <![CDATA[Glioblastoma multiforme is one of the most lethal cancers; when in grade IV, patients only have a median overall survival of 14.6 months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708514</guid>
      <pubDate>Wed, 15 May 2024 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708514-rz-001-shows-promise-for-treating-glioblastoma-multiforme</link>
    </item>
  </channel>
</rss>
